Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

VITAE

Financiado

VIrTual BrAin PErfusion Assessing cerebrovascular function by High Performance...

VIrTual BrAin PErfusion Assessing cerebrovascular function by High Performance Computing from 3D brain vessel network data for vascular targeted drug development in neurodegenerative diseases. With the recent discovery that brain blood flow decreases — in a statistical and epidemiologic sense — before accumulation of neurotoxic deposits (e.g. amyloid and tau) and before any measurable cognitive deficits, the brain vascu... ver más

31/10/2020

CNRS

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-10-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2018-PoC: ERC Proof of Concept Grant

I+D

Cerrada hace 6 años

0% 100% 100%

3 Participantes

CNRS

149.74K€ | Lider

LABORATORIOS DEITERS

312.24K€ | Participante

CNRS INNOVATION

12.50K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 25 meses Fecha Inicio: 2018-09-28
Fecha Fin: 2020-10-31

Presupuesto del proyecto 150K€

Descripción del proyecto With the recent discovery that brain blood flow decreases — in a statistical and epidemiologic sense — before accumulation of neurotoxic deposits (e.g. amyloid and tau) and before any measurable cognitive deficits, the brain vascular system is increasingly recognized as a key player in the development of Alzheimer’s Disease (AD). This opens the way for the development of new disease-modifying therapeutic strategies targeting vascular pathways at early stages of AD, i.e. long before the neurodegenerative process becomes established and symptomatic. The central idea of this POC proposal is that High Performance Computing (HPC) assessment of cerebrovascular function from quantitative vessel network data will tremendously accelerate vascular-targeted drug development for neurodegenerative brain diseases. One of the key outputs of the research conduced in the ERC Consolidator BrainMicroFlow is indeed a HPC platform for modeling blood flow, nutrient delivery and metabolic waste removal in large anatomical vessel networks of the brain. However, using this platform requires advanced and specific parallel programing skills, which are in general not available, neither in the research nor in the R&D industrial environments focused on Alzheimer Disease. Thus, our aims are 1/ to upgrade the technical specifications of this platform and to develop a user-friendly and versatile interface, documentation and support, to create a new software, called VITAE, meeting the industry standards, that users with minimal programming skills could use on their own or local computational resources; 2/ to optimize the HPC capacities of VITAE so that its performances can reach the scale of a whole mouse brain (VITAE4WholeBrain), that could be accessed as a service provided to end users by partnering computational centers; 3/ to assess the market and the competitors for both versions of VITAE; 4/ to determine IPR position and strategy, and 5/ to explore licensing and partnership possibilities.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores